<div id="readability-page-1">New insider activity at Alumis Inc. ( (ALMS) ) has taken place on January 13, 2026.<h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul> Director Srinivas Akkaraju has made a significant insider purchase of Alumis Inc. stock, acquiring 588,235 shares in a single transaction. The deal carries a total value of $9,999,995, underscoring a substantial show of confidence in Alumis Inc. from within the company’s leadership. Recent Updates on ALMS stock Over the last 24 hours, Alumis Inc. has been in focus after positive Phase 3 results for its lead drug envudeucitinib in moderate-to-severe plaque psoriasis, which several analysts say make the data look competitive and materially reduce regulatory approval risk while expanding the drug’s long‑term revenue potential, prompting multiple upward revisions to their price expectations. H.C. Wainwright highlighted that the Phase 3 readout reset expectations for the oral TYK2 inhibitor landscape, citing both lower approval risk and a higher revenue ceiling as key drivers behind its more optimistic long‑term outlook. Morgan Stanley similarly raised its expectations after boosting its estimated probability of success for the psoriasis indication, reflecting stronger confidence in future cash flows from envudeucitinib. In parallel, Alumis launched and upsized a common stock offering—ultimately structuring a 17.65M‑share underwriting at $17 per share with an option for additional shares, increasing the total deal size from $175M to roughly $300M–$345M—to bolster its balance sheet and financial flexibility following the trial success. While the offering introduces dilution that can pressure shares in the near term, the company’s enhanced capital position, combined with the de‑risking of its late‑stage asset, underpins the more constructive analyst assumptions embedded in the recent target updates, even as AI-based analysis flags ongoing concerns around heavy cash burn, negative profitability, and legal risk. Recent trading has been active, with the stock previously more than doubling on the psoriasis data, and technical indicators currently skewing positive despite some near‑term consolidation around the secondary pricing level. Spark’s Take on ALMS Stock According to Spark, TipRanks’ AI Analyst, ALMS is a Neutral. The score is held back primarily by very large losses and heavy cash burn (financial performance), partially offset by strong upward technical momentum and favorable recent clinical results. Valuation support is limited due to negative earnings, and the sizable equity raise improves funding runway but introduces dilution. To see Spark’s full report on ALMS stock, click here. More about Alumis Inc. YTD Price Performance: 116.09% Average Trading Volume: 2,481,096 Technical Sentiment Signal: Buy Current Market Cap: $2.39B</div>

ALMS

Insider Makes Bold Multimillion-Dollar Bet on Alumis Inc.